Liposomal bupivacaine

Tier C — Watch / trade

Pacira Pharmaceuticals Inc

Originator

2011

First approval

Expiry (public)

$0.6B ▲

Peak sales

Small molecule

Type

Targets：SCNA

Brand：Exparel liposomal, Exparel

Indications (approved)：Pain, Postoperative pain

Regional status

Approved

2011-10-28

Approved

2020-11-16

China

Approved

2022-11-30

Japan

Factories producing this API2

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

2 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Liposomal bupivacaine?

Approved indications include: Pain, Postoperative pain.

When does the Liposomal bupivacaine patent expire?

No public expiry year is available for Liposomal bupivacaine yet; this page updates once verified.

How do I get a quote for Liposomal bupivacaine intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29